An alternative signaling pathway, controlled by FGFR1 (fibroblast growth factor receptor 1), steps in and ensures growth and survival. "With the help of such 'bypasses,' tumors react to external ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

analyzed the genomes of 15,382 tumor samples that had been obtained ... and fibroblast growth factor receptor 1 (FGFR1), are validated drug targets for therapeutic intervention, others remain ...

Session: Rapid Oral Abstract – Gynecologic Cancer. June 3, 9:42 a.m. ET (8:42 a.m. CT)) A Phase 2 Study of Pemigatinib for Pre-treated Glioblastoma or Other Gliomas with Activating FGFR1-3 ...

FGFR inhibitors are well-established oncogenic drivers in multiple diseases, but approved medicines fail to capture the full landscape of FGFR altered tumor types, with FGFR1-mediated ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

Impaired FGFR signaling has been associated with different pathologies, including growth disorders, degenerative diseases and cancer. Thus, targeting FGFR signaling can offer significant therapeutic ...

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting ...